Novel targets mediating resistance to EGFR/c-Met tyrosine kinase inhibitors in NSCLC.

被引：0
|
作者：
Jacobs, Ryan [1 ]
Fong, Jason [1 ]
Moravec, David [1 ]
Botting, Greg [1 ]
Bomgarden, Ryan [2 ]
Rogers, John [2 ]
Viner, Rosa [3 ]
Blank, Michael [3 ]
Puri, Neelu [1 ]
机构：
[1] Univ Illinois, Rockford, IL USA
[2] Thermo Fisher Sci, Rockford, IL USA
[3] Thermo Fisher Sci, San Jose, CA USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-5653
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5653
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Novel targets mediating resistance to EGFR/c-Met tyrosine kinase inhibitors in NSCLC
    Jacobs, Ryan
    Fong, Jason
    Bomgarden, Ryan
    Rogers, John
    Puri, Neelu
    CANCER RESEARCH, 2012, 72
  • [2] Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
    Botting, Gregory M.
    Rastogi, Ichwaku
    Chhabra, Gagan
    Nlend, Marie
    Puri, Neelu
    PLOS ONE, 2015, 10 (08):
  • [3] C-Met, a marker of resistance to EGFR inhibitors in NSCLC
    Engelman, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 22 - 22
  • [4] Targeting c-Met overexpression for overcoming acquired resistance to EGFR TKIs in NSCLC.
    Gou, Lanying
    Wu, Yi-Long
    Yang, Jinji
    Zhang, Xuchao
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Mechanism of resistance to c-Met tyrosine kinase inhibitors in human melanoma
    Etnyre, Deven
    Fong, Jason
    Bertram, Ceyda
    Puri, Neelu
    CANCER RESEARCH, 2012, 72
  • [6] Mechanisms of EGFR and c-Met inhibitor resistance in NSCLC
    Fong, Jason T.
    Puri, Neelu
    CANCER RESEARCH, 2011, 71
  • [7] Clonal dominance of EGFR and efficacy of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC.
    Ai, Xinghao
    Chen, Rongrong
    Cui, Jiuwei
    Zhang, Jiexia
    Lin, Wen
    Xie, Congying
    Hu, Xiaohua
    Zhang, Junping
    Jiao, Xiaodong
    Rao, Chuangzhou
    Yang, Weihua
    Chang, Lianpeng
    Xia, Xuefeng
    Yi, Xin
    Lu, Shun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
    Baldacci, Simon
    Mazieres, Julien
    Tomasini, Pascale
    Girard, Nicolas
    Guisier, Florian
    Audigier-Valette, Clarisse
    Monnet, Isabelle
    Wislez, Marie
    Perol, Maurice
    Do, Pascal
    Dansin, Eric
    Leduc, Charlotte
    Leprieur, Etienne Giroux
    Moro-Sibilot, Denis
    Tulasne, David
    Kherrouche, Zoulika
    Labreuche, Julien
    Cortot, Alexis B.
    ONCOTARGET, 2017, 8 (62) : 105103 - 105114
  • [9] Optimization techniques for novel c-Met kinase inhibitors
    Sun, Zhi-Gang
    Yang, Yong-An
    Zhang, Zhi-Gang
    Zhu, Hai-Liang
    EXPERT OPINION ON DRUG DISCOVERY, 2019, 14 (01) : 59 - 69
  • [10] Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer
    Ahn, So Yeong
    Kim, Jin
    Kim, Min A.
    Choi, Jiwoon
    Kim, Woo Ho
    ANTICANCER RESEARCH, 2017, 37 (03) : 1127 - 1138
12345